Pembrolizumab is a pioneering checkpoint inhibitor that empowers the immune system to fight cancer by blocking PD-1 receptors on T-cells. Normally, cancer cells exploit PD-L1 to turn off T-cells, evading immune attack. Pembrolizumab removes this “brake,” allowing T-cells to recognize and destroy tumors. This approach shifts cancer therapy from directly targeting cells to enhancing the body’s natural defenses.
Its impact spans multiple cancers. In non-small cell lung cancer (NSCLC), pembrolizumab serves as a first-line therapy, often combined with chemotherapy. It is standard care for advanced melanoma, recurrent/metastatic head and neck cancer, and kidney cancer (often with targeted therapy). It also treats classical Hodgkin lymphoma and has a landmark tissue-agnostic approval for MSI-H/dMMR solid tumors. Additional approvals include triple-negative breast, bladder, gastric, cervical, esophageal, and hepatocellular cancers, demonstrating precision medicine based on tumor biology rather than location.
Clinical trials show durable responses, complete remissions in some patients, and sustained long-term benefits. Immune-related side effects are generally manageable. Ongoing research explores combinations, earlier-stage treatment, and broader patient access, positioning pembrolizumab as a transformative, evolving cornerstone of cancer immunotherapy.